Figure 1

Number (and percentage values siding the bars) of recombinant proteins approved as biopharmaceuticals in different production systems. Data has been adapted from Table 1 in [3]. Exubera, an inhalated recombinant human insulin produced in E. coli has been omitted since Pfizer stopped its marketing in January 2008. Two recently FDA approved products Xyntha and Recothrom produced both in CHO cells have also been added.